JP4904402B2 - ムスカリン受容体アンタゴニストとしての（ヘテロ）アリールシクロヘプタンカルボン酸のキヌクリジン誘導体 - Google Patents

ムスカリン受容体アンタゴニストとしての（ヘテロ）アリールシクロヘプタンカルボン酸のキヌクリジン誘導体 Download PDF

Info

Publication number
JP4904402B2
JP4904402B2 JP2009536788A JP2009536788A JP4904402B2 JP 4904402 B2 JP4904402 B2 JP 4904402B2 JP 2009536788 A JP2009536788 A JP 2009536788A JP 2009536788 A JP2009536788 A JP 2009536788A JP 4904402 B2 JP4904402 B2 JP 4904402B2
Authority
JP
Japan
Prior art keywords
alkyl
oxy
carbonyl
phenylcycloheptyl
octane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009536788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509391A (ja
JP2010509391A5 (cg-RX-API-DMAC7.html
Inventor
ローナン・フォード
アンドリュー・メイザー
アントニオ・メーテ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2010509391A publication Critical patent/JP2010509391A/ja
Publication of JP2010509391A5 publication Critical patent/JP2010509391A5/ja
Application granted granted Critical
Publication of JP4904402B2 publication Critical patent/JP4904402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
JP2009536788A 2006-11-14 2007-11-13 ムスカリン受容体アンタゴニストとしての（ヘテロ）アリールシクロヘプタンカルボン酸のキヌクリジン誘導体 Expired - Fee Related JP4904402B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86566706P 2006-11-14 2006-11-14
US60/865,667 2006-11-14
US86938406P 2006-12-11 2006-12-11
US60/869,384 2006-12-11
PCT/GB2007/004350 WO2008059245A1 (en) 2006-11-14 2007-11-13 Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists

Publications (3)

Publication Number Publication Date
JP2010509391A JP2010509391A (ja) 2010-03-25
JP2010509391A5 JP2010509391A5 (cg-RX-API-DMAC7.html) 2011-08-18
JP4904402B2 true JP4904402B2 (ja) 2012-03-28

Family

ID=39048793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536788A Expired - Fee Related JP4904402B2 (ja) 2006-11-14 2007-11-13 ムスカリン受容体アンタゴニストとしての（ヘテロ）アリールシクロヘプタンカルボン酸のキヌクリジン誘導体

Country Status (29)

Country Link
US (2) US8207193B2 (cg-RX-API-DMAC7.html)
EP (2) EP2094694B1 (cg-RX-API-DMAC7.html)
JP (1) JP4904402B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090078828A (cg-RX-API-DMAC7.html)
AR (1) AR063804A1 (cg-RX-API-DMAC7.html)
AT (1) ATE496916T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007321019B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718750A2 (cg-RX-API-DMAC7.html)
CA (1) CA2669326A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003260A1 (cg-RX-API-DMAC7.html)
CO (1) CO6160312A2 (cg-RX-API-DMAC7.html)
CY (1) CY1111351T1 (cg-RX-API-DMAC7.html)
DE (1) DE602007012300D1 (cg-RX-API-DMAC7.html)
DK (1) DK2094694T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP099338A (cg-RX-API-DMAC7.html)
HR (1) HRP20110178T1 (cg-RX-API-DMAC7.html)
IL (1) IL198314A (cg-RX-API-DMAC7.html)
MX (1) MX2009004780A (cg-RX-API-DMAC7.html)
MY (1) MY148392A (cg-RX-API-DMAC7.html)
NO (1) NO20092224L (cg-RX-API-DMAC7.html)
NZ (1) NZ576679A (cg-RX-API-DMAC7.html)
PE (1) PE20081164A1 (cg-RX-API-DMAC7.html)
PL (1) PL2094694T3 (cg-RX-API-DMAC7.html)
PT (1) PT2094694E (cg-RX-API-DMAC7.html)
RS (1) RS51650B (cg-RX-API-DMAC7.html)
RU (1) RU2456286C2 (cg-RX-API-DMAC7.html)
SA (1) SA07280616B1 (cg-RX-API-DMAC7.html)
TW (1) TW200825084A (cg-RX-API-DMAC7.html)
WO (1) WO2008059245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500973A (ja) * 2006-07-21 2010-01-14 マース インコーポレーテッド アルギナーゼ濃度／活性の改善
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EA017627B1 (ru) * 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
BRPI0912657A2 (pt) * 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
RU2011101664A (ru) * 2008-06-20 2012-07-27 Астразенека Аб (Se) Фармацевтическая композиция, содержащая 4-гидрокси-2-оксо-2, 3-дигидро-1, 3-бензотиазол-7-ильное соединение, для модулирования активности бета2- адренорецепторов
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AR076590A1 (es) * 2009-05-19 2011-06-22 Vivia Biotech Sl Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
ES2545812T3 (es) * 2010-06-22 2015-09-16 Chiesi Farmaceutici S.P.A. Derivados aminoéster de alcaloides y composición medicinal de estos
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
AU2013257139B2 (en) 2012-04-30 2018-02-22 Biothera, Inc. Beta-glucan immunotherapeutic methods
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) * 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (cg-RX-API-DMAC7.html) 1942-12-16
DE2104179C3 (de) 1971-01-29 1980-10-02 Knoll Ag, 6700 Ludwigshafen exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
FR2155927A1 (en) 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
FR2168881A1 (en) 1972-01-25 1973-09-07 Synthelabo Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
FR2208649A1 (en) 1972-12-01 1974-06-28 Synthelabo 1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IL77458A (en) 1985-01-14 1990-07-26 Eisai Co Ltd Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
WO1992015590A1 (en) 1991-03-07 1992-09-17 G.D. Searle & Co. New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
KR20000029703A (ko) 1996-07-29 2000-05-25 존 헤덴스트룀 아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ES2195121T3 (es) 1996-11-11 2003-12-01 Christian R Noe Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
JP2004504391A (ja) 2000-07-07 2004-02-12 アンギオジェン・ファーマシューティカルズ・リミテッド 血管新生阻害剤としてのコルキノール誘導体
EP1345937B1 (en) * 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
NZ526674A (en) 2000-12-28 2005-03-24 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
JP2004532874A (ja) 2001-04-03 2004-10-28 アリックス セラピューティクス 抗コリン作用性化合物および使用法
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
CA2499314C (en) 2002-10-11 2010-08-24 Pfizer Inc. Indole derivatives as beta-2 agonists
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PE20050231A1 (es) 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
AU2004285592B2 (en) 2003-11-03 2010-02-18 Norton Healthcare, Ltd. Soft steroid compositions for use in dry powder inhalers
WO2006025324A1 (ja) 2004-08-30 2006-03-09 Ono Pharmaceutical Co., Ltd. トロパン化合物およびそれらを有効成分として含有する医薬組成物
US20090105221A1 (en) 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
RS20070076A (sr) 2004-10-29 2008-09-29 Astrazeneca Ab., Novi derivati sulfonamida kao modulatori glukokortikoidnog receptora za lečenje zapaljenskih bolesti
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
TW200722418A (en) 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
US20080194632A1 (en) 2005-08-01 2008-08-14 Astrazeneca Ab Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases
TW200738635A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
US20090182033A1 (en) 2005-12-16 2009-07-16 Argenta Discovery Ltd. Cyclic Amine Derivatives and Their Uses
WO2007123465A1 (en) 2006-04-24 2007-11-01 Astrazeneca Ab New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder
JP2009543860A (ja) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
JP2010501533A (ja) 2006-08-21 2010-01-21 アージェンタ ディスカバリー リミテッド Ｍ３レセプター調節物質として有用な窒素含有複素環化合物
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2008059239A1 (en) 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
ATE555111T1 (de) 2006-12-19 2012-05-15 Astrazeneca Ab Chinuclidinol-derivate als muscarinrezeptor- antagonisten
WO2008075006A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
WO2008096094A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702382D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
NZ578475A (en) 2007-02-07 2011-05-27 Pulmagen Therapeutics Synergy Napadisylate salt of a muscarinic m3 antagonist
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702414D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
JP2010519193A (ja) 2007-02-15 2010-06-03 アージェンタ ディスカバリー リミテッド Ｍ３ムスカリン受容体としての複素環式誘導体
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
WO2008149053A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Ltd. Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
WO2009098453A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
RS52557B (sr) 2008-02-06 2013-04-30 Pulmagen Therapeutics (Synergy) Limited Jedinjenja
WO2009098455A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
BRPI0912657A2 (pt) 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
GB0808709D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0808707D0 (en) 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
EA017627B1 (ru) * 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
GB0811100D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2009153536A1 (en) 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010018352A1 (en) 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814729D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
KR20110045053A (ko) 2008-08-12 2011-05-03 아스트라제네카 아베 2-히드록시-에탄술포네이트 염
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Also Published As

Publication number Publication date
JP2010509391A (ja) 2010-03-25
NZ576679A (en) 2011-04-29
PL2094694T3 (pl) 2011-05-31
HRP20110178T1 (hr) 2011-04-30
BRPI0718750A2 (pt) 2013-12-03
ATE496916T1 (de) 2011-02-15
CO6160312A2 (es) 2010-05-20
EP2256117A1 (en) 2010-12-01
RU2456286C2 (ru) 2012-07-20
CY1111351T1 (el) 2015-08-05
IL198314A0 (en) 2010-02-17
US8207193B2 (en) 2012-06-26
ECSP099338A (es) 2009-06-30
EP2094694B1 (en) 2011-01-26
HK1134091A1 (en) 2010-04-16
WO2008059245A1 (en) 2008-05-22
IL198314A (en) 2013-06-27
CA2669326A1 (en) 2008-05-22
KR20090078828A (ko) 2009-07-20
NO20092224L (no) 2009-06-22
AR063804A1 (es) 2009-02-18
MX2009004780A (es) 2009-05-21
SA07280616B1 (ar) 2010-11-22
DE602007012300D1 (de) 2011-03-10
EP2094694A1 (en) 2009-09-02
PT2094694E (pt) 2011-03-17
TW200825084A (en) 2008-06-16
RS51650B (sr) 2011-10-31
US20100029713A1 (en) 2010-02-04
CL2007003260A1 (es) 2008-05-23
DK2094694T3 (da) 2011-04-04
US20130005695A1 (en) 2013-01-03
AU2007321019A1 (en) 2008-05-22
MY148392A (en) 2013-04-15
AU2007321019B2 (en) 2011-04-21
PE20081164A1 (es) 2008-10-31
RU2009115829A (ru) 2010-12-20

Similar Documents

Publication Publication Date Title
JP4904402B2 (ja) ムスカリン受容体アンタゴニストとしての（ヘテロ）アリールシクロヘプタンカルボン酸のキヌクリジン誘導体
JP4604129B2 (ja) ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体
JP4837800B2 (ja) ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
WO2009139709A1 (en) Quinuclidine derivatives and their use as muscarinic receptor antagonists for the treatment of asthma and chronic obstructive pulmonary disease (copd)
JP2009534463A (ja) 例えば慢性気管支閉塞、喘息および過活動膀胱の処置に有用な、ムスカリンｍ３受容体アンタゴニスト活性を有する環状アミノアルコールの新規アルキルエステル
WO2009139710A1 (en) Quinuclidine derivatives and their use as muscarinic receptor antagonists
WO2008059239A1 (en) Novel compounds 514
WO2008075006A1 (en) Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
CN101535306B (zh) 作为毒蕈碱受体拮抗剂的（杂）芳基环庚基甲酸的奎宁环衍生物
CN101490003A (zh) 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
JP2011195593A (ja) ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
ES2357988T3 (es) Derivados de quiniclidina de ácido(hetero)arilcicloheptanocarboxílico como antagonistas del receptor muscarínico.
WO2010018352A1 (en) Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
HK1148001A (en) Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
HK1134091B (en) Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
HK1158205A (en) Quinuclidine derivatives as muscarinic m3 receptor antagonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110630

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110630

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120106

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150113

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees